Dear All, On behalf of Purdue University's Davidson School of Chemical Engineering, we are glad to announce our upcoming Graduate Seminar Series Lecturer Dr. Kelvin Lee from the Gore Professor of Chemical & Biomolecular Engineering, Institute Director of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) at University of Delaware. He will be visiting Purdue University on Tuesday, December 3, 2019. You will find further detail regarding the lecture at the end of this email. If you have any questions, please do not hesitate to contact me. Sincerely, Lauren Hays Secretary/FRNY 1060 Purdue University | Charles D. Davidson School of Chemical Engineering West Lafayette, IN 47907 Phone: 765-494-4050 Fax: 765-494-0805 hays14@purdue.edu<mailto:hays14@purdue.edu> [https://marketing.purdue.edu/Email/TemplateSets/ChE/Templates/Template04/Images/DSCE-BG-PU_White_RM.png]<https://engineering.purdue.edu/ChE> Graduate Seminar Series [http://marketing.purdue.edu/Email/TemplateSets/ChE/Archive/Email00046/KHLsm....] Dr. Kelvin Lee Gore Professor of Chemical & Biomolecular Engineering, Institute Director of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), Department of Chemical and Biomolecular Engineering, University of Delaware Bio: Kelvin H. Lee is Gore Professor of Chemical and Biomolecular Engineering at the University of Delaware and is Director of NIIMBL: the National Institute for Innovation in Manufacturing Biopharmaceuticals, one of 14 Manufacturing USA Institutes. He received a BSE in Chemical Engineering from Princeton and PhD in Chemical Engineering from Caltech. He spent several years in the Biotechnology Institute at the ETH in Zurich, Switzerland and also completed a postdoc in Caltech's Biology Division. Prior to his current appointment, he was on the faculty at Cornell University where he held the titles of: Samuel C. and Nancy M. Fleming Chair Professor, Professor in the School of Chemical and Biomolecular Engineering, Director of the Cornell Institute for Biotechnology, and Director of the New York State Center for Life Science Enterprise. ******* ******* "A Host Cell Protein Contaminant that May Impact Antibody Drug Product Stability" Tuesday, December 3, 2019 3:00 p.m. - 4:15 p.m. FRNY G140 - Reception at 2:30 p.m. in Henson Atrium - Abstract: Chinese hamster ovary (CHO) cells are the preferred platform for biotherapeutic protein production. Monoclonal antibodies (mAbs) alone are predicted to reach global sales of 125 billion USD in 2020 and are used to treat many oncological, immunological and cardiovascular diseases. During the production of therapeutic proteins by CHO cells, host cell proteins (HCPs) are also secreted by the cells. Certain HCPs, if not removed during subsequent purification processes, have been shown to cause immunogenic responses in patients. In this presentation, we will discuss the role of having an accurate, high quality genome, in the identification and characterization of HCPs as well as in the identification and characterization of particularly problematic HCPs that are difficult to remove and can impact product stability. We will also discuss how a large-scale public-private partnership, the National Institute for Innovation in Manufacturing Biopharmaceuticals, brings together Purdue scientists to work with colleagues from government, industry, and academia to tackle biopharmaceutical manufacturing technology innovation. ******* ******* Davidson School of Chemical Engineering<https://engineering.purdue.edu/ChE> Purdue University West Lafayette, IN 47907 (765) 494-4050<tel:+17654944050> (c) 2019 Purdue University<http://www.purdue.edu/purdue/disclaimer.html> All rights reserved An equal access/equal opportunity university<http://www.purdue.edu/purdue/ea_eou_statement.html>